Barricaid is designed to prevent reherniation and reoperation for patients with large annular defects after lumbar discectomy, according to a news release. It has been used in more than 10,000 patients and is supported by clinical studies.
“This new coverage policy will give Cigna members access to the Barricaid technology and help to reduce the burden of reherniation and reoperation for discectomy patients when deemed medically necessary by their surgeo,” Intrinsic Therapeutics founder Greg Lambrecht said in the release.
The new Cigna policy went into effect June 15.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
